PharmaCorp Rx Inc.
PCRX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.52M | 3.49M | 3.18M | 2.79M | 3.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.52M | 3.49M | 3.18M | 2.79M | 3.14M |
| Cost of Revenue | 3.39M | 2.06M | 1.91M | 1.66M | 1.95M |
| Gross Profit | 2.13M | 1.42M | 1.26M | 1.13M | 1.19M |
| SG&A Expenses | 2.34M | 1.62M | 1.37M | 842.00K | 800.50K |
| Depreciation & Amortization | 245.20K | 161.40K | 136.30K | 130.60K | 136.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.97M | 3.85M | 3.42M | 2.63M | 2.89M |
| Operating Income | -456.50K | -362.20K | -239.00K | 159.00K | 255.90K |
| Income Before Tax | -388.80K | -310.80K | -164.60K | 252.30K | 440.20K |
| Income Tax Expenses | 243.50K | -13.70K | 114.20K | 75.10K | -76.50K |
| Earnings from Continuing Operations | -632.30K | -297.10K | -278.80K | 177.20K | 516.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -21.70K | -13.30K | 1.20K | -8.60K | 25.80K |
| Net Income | -654.00K | -310.40K | -277.60K | 168.60K | 542.40K |
| EBIT | -456.50K | -362.20K | -239.00K | 159.00K | 255.90K |
| EBITDA | -160.90K | -219.20K | -118.90K | 274.00K | 358.50K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 148.67M | 117.30M | 117.30M | 117.30M | 117.54M |
| Average Diluted Shares Outstanding | 148.67M | 117.30M | 117.30M | 117.30M | 117.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |